CN108048573A - 用于确定癌症对象之预后的方法和核酸 - Google Patents
用于确定癌症对象之预后的方法和核酸 Download PDFInfo
- Publication number
- CN108048573A CN108048573A CN201810020458.1A CN201810020458A CN108048573A CN 108048573 A CN108048573 A CN 108048573A CN 201810020458 A CN201810020458 A CN 201810020458A CN 108048573 A CN108048573 A CN 108048573A
- Authority
- CN
- China
- Prior art keywords
- cancer
- treatment
- sequence
- methylated
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 485
- 201000011510 cancer Diseases 0.000 title claims abstract description 334
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 111
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 98
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 98
- 238000004393 prognosis Methods 0.000 title claims abstract description 88
- 238000000034 method Methods 0.000 title abstract description 248
- 238000011282 treatment Methods 0.000 claims abstract description 229
- 238000007069 methylation reaction Methods 0.000 claims abstract description 189
- 230000011987 methylation Effects 0.000 claims abstract description 186
- 108020004414 DNA Proteins 0.000 claims description 331
- 108090000623 proteins and genes Proteins 0.000 claims description 207
- 239000000523 sample Substances 0.000 claims description 206
- 239000012634 fragment Substances 0.000 claims description 153
- 239000012472 biological sample Substances 0.000 claims description 90
- 102100028024 Septin-9 Human genes 0.000 claims description 88
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 79
- 238000002203 pretreatment Methods 0.000 claims description 79
- 239000003153 chemical reaction reagent Substances 0.000 claims description 76
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 claims description 72
- 125000003729 nucleotide group Chemical group 0.000 claims description 72
- 108091029430 CpG site Proteins 0.000 claims description 70
- 239000002773 nucleotide Substances 0.000 claims description 69
- 230000000295 complement effect Effects 0.000 claims description 66
- 230000003321 amplification Effects 0.000 claims description 65
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 65
- 238000001356 surgical procedure Methods 0.000 claims description 61
- 206010009944 Colon cancer Diseases 0.000 claims description 59
- 238000009396 hybridization Methods 0.000 claims description 53
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 47
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 44
- 230000014509 gene expression Effects 0.000 claims description 39
- 101000632056 Homo sapiens Septin-9 Proteins 0.000 claims description 31
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 229940104302 cytosine Drugs 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 208000029742 colonic neoplasm Diseases 0.000 claims description 16
- 238000002271 resection Methods 0.000 claims description 15
- 229940035893 uracil Drugs 0.000 claims description 12
- 238000002512 chemotherapy Methods 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 238000009169 immunotherapy Methods 0.000 claims description 5
- 238000001959 radiotherapy Methods 0.000 claims description 5
- 210000003608 fece Anatomy 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 238000002626 targeted therapy Methods 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims description 3
- 230000002489 hematologic effect Effects 0.000 claims description 3
- 230000002262 irrigation Effects 0.000 claims description 2
- 238000003973 irrigation Methods 0.000 claims description 2
- 230000008520 organization Effects 0.000 claims description 2
- 238000001514 detection method Methods 0.000 abstract description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 121
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 82
- 210000001519 tissue Anatomy 0.000 description 77
- 238000003752 polymerase chain reaction Methods 0.000 description 56
- 238000004458 analytical method Methods 0.000 description 54
- 238000003556 assay Methods 0.000 description 47
- 108091008146 restriction endonucleases Proteins 0.000 description 43
- 101150042012 SEPTIN9 gene Proteins 0.000 description 39
- 108090000765 processed proteins & peptides Proteins 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 36
- 239000000872 buffer Substances 0.000 description 35
- 102000004196 processed proteins & peptides Human genes 0.000 description 35
- 230000004083 survival effect Effects 0.000 description 35
- 239000000047 product Substances 0.000 description 34
- 108091028043 Nucleic acid sequence Proteins 0.000 description 31
- 210000002381 plasma Anatomy 0.000 description 31
- 229920001184 polypeptide Polymers 0.000 description 29
- 206010061289 metastatic neoplasm Diseases 0.000 description 28
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 27
- 230000001394 metastastic effect Effects 0.000 description 27
- 108050002584 Septin 9 Proteins 0.000 description 26
- 238000007855 methylation-specific PCR Methods 0.000 description 24
- 230000000692 anti-sense effect Effects 0.000 description 23
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical group OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 22
- 108091029523 CpG island Proteins 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 239000000090 biomarker Substances 0.000 description 18
- 108091093037 Peptide nucleic acid Proteins 0.000 description 15
- 206010027476 Metastases Diseases 0.000 description 14
- 239000011324 bead Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 238000002372 labelling Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 230000000903 blocking effect Effects 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 238000012544 monitoring process Methods 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 238000002493 microarray Methods 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 108010006785 Taq Polymerase Proteins 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000003260 vortexing Methods 0.000 description 9
- 108091081021 Sense strand Proteins 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 7
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 7
- 230000007067 DNA methylation Effects 0.000 description 7
- 102000006382 Ribonucleases Human genes 0.000 description 7
- 108010083644 Ribonucleases Proteins 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000010195 expression analysis Methods 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000010837 poor prognosis Methods 0.000 description 7
- -1 pyrosulfite Chemical compound 0.000 description 7
- 238000004445 quantitative analysis Methods 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical class CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 6
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 6
- 108020004518 RNA Probes Proteins 0.000 description 6
- 239000003391 RNA probe Substances 0.000 description 6
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 6
- 238000011226 adjuvant chemotherapy Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 239000002751 oligonucleotide probe Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000011535 reaction buffer Substances 0.000 description 6
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- 238000000018 DNA microarray Methods 0.000 description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 238000000636 Northern blotting Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000001976 enzyme digestion Methods 0.000 description 5
- 230000001973 epigenetic effect Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical group N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000030933 DNA methylation on cytosine Effects 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 101000712956 Homo sapiens Ras association domain-containing protein 2 Proteins 0.000 description 4
- 102100033242 Ras association domain-containing protein 2 Human genes 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 210000000664 rectum Anatomy 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 3
- 206010061819 Disease recurrence Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 230000006326 desulfonation Effects 0.000 description 3
- 238000005869 desulfonation reaction Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000001952 enzyme assay Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001917 fluorescence detection Methods 0.000 description 3
- 230000006607 hypermethylation Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000006277 sulfonation reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010076804 DNA Restriction Enzymes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 101150041202 RASSF2 gene Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 101000864964 Rattus norvegicus Septin-9 Proteins 0.000 description 2
- 108050004875 Septin Proteins 0.000 description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004451 qualitative analysis Methods 0.000 description 2
- 238000012113 quantitative test Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000011897 real-time detection Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012764 semi-quantitative analysis Methods 0.000 description 2
- 229910000077 silane Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- AOSFMYBATFLTAQ-UHFFFAOYSA-N 1-amino-3-(benzimidazol-1-yl)propan-2-ol Chemical compound C1=CC=C2N(CC(O)CN)C=NC2=C1 AOSFMYBATFLTAQ-UHFFFAOYSA-N 0.000 description 1
- BRRSNXCXLSVPFC-UHFFFAOYSA-N 2,3,4-Trihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1O BRRSNXCXLSVPFC-UHFFFAOYSA-N 0.000 description 1
- PYQVCYCHUWIDIS-UHFFFAOYSA-N 2,5,7,8-tetramethyl-3,4-dihydro-2h-chromen-6-ol Chemical compound OC1=C(C)C(C)=C2OC(C)CCC2=C1C PYQVCYCHUWIDIS-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 241000102542 Kara Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 101100409186 Mus musculus Prg4 gene Proteins 0.000 description 1
- PJKKQFAEFWCNAQ-UHFFFAOYSA-N N(4)-methylcytosine Chemical class CNC=1C=CNC(=O)N=1 PJKKQFAEFWCNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010067777 Oncologic complication Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 102000015602 Septin Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000001369 bisulfite sequencing Methods 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 239000002812 cholic acid derivative Substances 0.000 description 1
- 150000001842 cholic acids Chemical class 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical class C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012325 curative resection Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000018732 detection of tumor cell Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 229940079826 hydrogen sulfite Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical group 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000768 polyamine Chemical group 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 208000019745 retinal vasculopathy with cerebral leukodystrophy Diseases 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- CSABAZBYIWDIDE-UHFFFAOYSA-N sulfino hydrogen sulfite Chemical class OS(=O)OS(O)=O CSABAZBYIWDIDE-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505919P | 2011-07-08 | 2011-07-08 | |
| US61/505,919 | 2011-07-08 | ||
| CN201280033813.XA CN103732759A (zh) | 2011-07-08 | 2012-07-09 | 用于确定癌症对象之预后的方法和核酸 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280033813.XA Division CN103732759A (zh) | 2011-07-08 | 2012-07-09 | 用于确定癌症对象之预后的方法和核酸 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108048573A true CN108048573A (zh) | 2018-05-18 |
Family
ID=46458553
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810020458.1A Pending CN108048573A (zh) | 2011-07-08 | 2012-07-09 | 用于确定癌症对象之预后的方法和核酸 |
| CN201280033813.XA Pending CN103732759A (zh) | 2011-07-08 | 2012-07-09 | 用于确定癌症对象之预后的方法和核酸 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280033813.XA Pending CN103732759A (zh) | 2011-07-08 | 2012-07-09 | 用于确定癌症对象之预后的方法和核酸 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10626462B2 (https=) |
| EP (1) | EP2729579B1 (https=) |
| JP (1) | JP6397762B2 (https=) |
| KR (1) | KR102046668B1 (https=) |
| CN (2) | CN108048573A (https=) |
| AU (1) | AU2012282528B2 (https=) |
| BR (1) | BR112014000443B1 (https=) |
| CA (1) | CA2840149C (https=) |
| DK (1) | DK2729579T3 (https=) |
| EA (1) | EA034232B1 (https=) |
| ES (1) | ES2654561T3 (https=) |
| HR (1) | HRP20180001T1 (https=) |
| HU (1) | HUE036036T2 (https=) |
| IL (1) | IL230303B (https=) |
| LT (1) | LT2729579T (https=) |
| MX (1) | MX358117B (https=) |
| NO (1) | NO2729579T3 (https=) |
| PH (1) | PH12014500063A1 (https=) |
| SI (1) | SI2729579T1 (https=) |
| WO (1) | WO2013007702A1 (https=) |
| ZA (1) | ZA201400089B (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114561452A (zh) * | 2022-03-10 | 2022-05-31 | 天津市人民医院 | mSEPT9作为预测结直肠癌患者术后复发风险标志物及用于评价化疗方案有效性的应用 |
| CN115029462A (zh) * | 2022-08-10 | 2022-09-09 | 中国农业科学院农业质量标准与检测技术研究所 | 一种动植物疫病的核酸标准物质、形貌模拟方法及其应用 |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10706957B2 (en) | 2012-09-20 | 2020-07-07 | The Chinese University Of Hong Kong | Non-invasive determination of methylome of tumor from plasma |
| US9732390B2 (en) | 2012-09-20 | 2017-08-15 | The Chinese University Of Hong Kong | Non-invasive determination of methylome of fetus or tumor from plasma |
| CA2951141C (en) * | 2014-06-04 | 2021-11-30 | Quest Diagnostics Investments Incorporated | Methylated markers for colorectal cancer |
| CN104745575B (zh) * | 2014-08-08 | 2019-03-12 | 博诚研究中心 | 用于检测细胞增殖性异常或疾病程度分级的基因组合物及其用途 |
| EP3766986B1 (en) | 2014-12-31 | 2022-06-01 | Guardant Health, Inc. | Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results |
| CN106148501A (zh) * | 2015-04-23 | 2016-11-23 | 博诚研究中心 | 一种检测Septin9基因甲基化的试剂盒及其应用 |
| US20180187246A1 (en) * | 2015-07-15 | 2018-07-05 | Universiteit Gent | Probes and a methylation in situ hybridization assay |
| JP6897970B2 (ja) * | 2015-09-08 | 2021-07-07 | 国立大学法人山口大学 | 大腸腫瘍の有無を検査する方法 |
| US11566284B2 (en) | 2016-08-10 | 2023-01-31 | Grail, Llc | Methods of preparing dual-indexed DNA libraries for bisulfite conversion sequencing |
| WO2018195217A1 (en) | 2017-04-19 | 2018-10-25 | Singlera Genomics, Inc. | Compositions and methods for library construction and sequence analysis |
| CN107385056A (zh) * | 2017-08-10 | 2017-11-24 | 上海时代基因医学科技有限公司 | 一种检测SEPT9基因不同Cpg岛甲基化的试剂盒及应用 |
| WO2019076949A1 (en) * | 2017-10-18 | 2019-04-25 | Deutsches Krebsforschungszentrum | MEANS AND METHODS FOR CLASSIFYING COLORECTAL CANCERS |
| WO2019108568A1 (en) * | 2017-11-29 | 2019-06-06 | The Regents Of The University Of Michigan | Compositions and methods for characterizing cancer |
| CN108796080B (zh) * | 2018-06-06 | 2022-06-07 | 苏州唯善生物科技有限公司 | 用于结直肠癌诊断、检测或筛查的引物和探针组 |
| CN109055552A (zh) * | 2018-08-23 | 2018-12-21 | 北京迈基诺基因科技股份有限公司 | 检测Septin9基因启动子是否甲基化的方法及其专用成套试剂 |
| CN112195243A (zh) * | 2020-09-22 | 2021-01-08 | 北京华大吉比爱生物技术有限公司 | 一种检测多基因甲基化的试剂盒及其应用 |
| KR102404750B1 (ko) | 2021-10-14 | 2022-06-07 | 주식회사 엔도믹스 | 세포 유리 dna를 이용한 대장암 진단을 위한 메틸화 마커 유전자 및 이의 용도 |
| KR102559496B1 (ko) * | 2022-04-26 | 2023-07-25 | 연세대학교 산학협력단 | 핵산의 메틸화 여부 확인용 조성물 및 핵산의 메틸화 여부를 확인하는 방법 |
| CN115248313A (zh) * | 2022-08-03 | 2022-10-28 | 中山市人民医院 | 肠癌外周血免疫细胞m5C标志物的应用 |
| CA3268032A1 (en) * | 2022-09-23 | 2024-03-28 | Flagship Pioneering Innovations Vi, Llc | NUCLEIC ACID AMPLIFICATION PROCESSES |
| WO2024107441A1 (en) * | 2022-11-14 | 2024-05-23 | Trustees Of Dartmouth College | Systemic biomarkers for the dynamic assessment of tumor burden and treatment efficacy in high grade gliomas |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005040421A2 (en) * | 2003-10-17 | 2005-05-06 | Martin Widschwendter | Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues |
| WO2007118704A2 (en) * | 2006-04-17 | 2007-10-25 | Epigenomics Ag | Methods and nucleic acids for the detection of colorectal cell proliferative disorders |
| CN101688239A (zh) * | 2007-02-12 | 2010-03-31 | 约翰·霍普金斯大学 | 结肠癌的早期检测和预后 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US412900A (en) | 1889-10-15 | roaers | ||
| US150000A (en) | 1874-04-21 | Improvement in cigar mouth - pieces | ||
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| SE501439C2 (sv) | 1993-06-22 | 1995-02-13 | Pharmacia Lkb Biotech | Sätt och anordning för analys av polynukleotidsekvenser |
| EP0734436B1 (en) | 1993-11-30 | 1999-04-14 | McGILL UNIVERSITY | Inhibition of dna methyltransferase |
| US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
| US5514758A (en) | 1994-09-30 | 1996-05-07 | The Goodyear Tire & Rubber Company | Process for making latex for high performance masking tape |
| US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US6251594B1 (en) | 1997-06-09 | 2001-06-26 | Usc/Norris Comprehensive Cancer Ctr. | Cancer diagnostic method based upon DNA methylation differences |
| DE19754482A1 (de) | 1997-11-27 | 1999-07-01 | Epigenomics Gmbh | Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke |
| US7700324B1 (en) | 1998-11-03 | 2010-04-20 | The Johns Hopkins University School Of Medicine | Methylated CpG island amplification (MCA) |
| US5958773A (en) | 1998-12-17 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense modulation of AKT-1 expression |
| US6331393B1 (en) | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| CN1150317C (zh) * | 1999-08-10 | 2004-05-19 | 中国医学科学院肿瘤医院肿瘤研究所 | 一种食管癌相关新基因 |
| WO2002024056A2 (en) * | 2000-09-20 | 2002-03-28 | Case Western Reserve University | METHODS AND COMPOSITIONS FOR DETECTING CANCERS ASSOCIATED WITH METHYLATION OF hMLH1PROMOTER DNA |
| DE10112515B4 (de) | 2001-03-09 | 2004-02-12 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungsmustern mit hoher Sensitivität |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| CN1187456C (zh) * | 2001-11-27 | 2005-02-02 | 暨南大学 | CpG岛甲基化检测试剂盒及其应用 |
| CA2549852A1 (en) | 2003-12-11 | 2005-06-30 | Epigenomics Ag | Method and nucleic acids for the improved treatment of breast cell proliferative disorders |
| JP4765058B2 (ja) | 2004-12-13 | 2011-09-07 | 国立大学法人 岡山大学 | 核酸修飾前の検体の前処理方法 |
| EA013634B1 (ru) | 2005-04-15 | 2010-06-30 | Эпиджиномикс Аг | Способы и нуклеиновые кислоты для анализов клеточных пролиферативных нарушений |
| WO2007085497A2 (en) | 2006-01-30 | 2007-08-02 | Epigenomics Ag | Markers for the prediction of outcome of anthracycline treatment |
| US9939441B2 (en) * | 2006-07-21 | 2018-04-10 | Epigenomics Ag | Methods and nucleic acids for analyses for cellular proliferative disorders |
| JP5378687B2 (ja) | 2007-03-02 | 2013-12-25 | エフ．ホフマン−ラ ロシュ アーゲー | Ｂａｓｐ１遺伝子および／またはｓｒｄ５ａ２遺伝子中のメチル化シトシンを利用する、肝臓癌、肝臓癌発症リスク、肝臓癌再発リスク、肝臓癌悪性度および肝臓癌の経時的進展の検出方法 |
| CN102159728A (zh) | 2008-09-19 | 2011-08-17 | 希森美康株式会社 | 乳腺癌转移的判断方法及血清的评价方法 |
| US8497066B2 (en) * | 2008-12-04 | 2013-07-30 | Rush University Medical Center | DNA methylation based test for monitoring efficacy of treatment |
| EP2309005B1 (en) * | 2009-08-03 | 2015-03-04 | Epigenomics AG | Methods for preservation of genomic DNA sequence complexity |
-
2012
- 2012-07-09 NO NO12732686A patent/NO2729579T3/no unknown
- 2012-07-09 KR KR1020147003119A patent/KR102046668B1/ko active Active
- 2012-07-09 CN CN201810020458.1A patent/CN108048573A/zh active Pending
- 2012-07-09 EP EP12732686.6A patent/EP2729579B1/en active Active
- 2012-07-09 SI SI201231155T patent/SI2729579T1/en unknown
- 2012-07-09 MX MX2014000116A patent/MX358117B/es active IP Right Grant
- 2012-07-09 LT LTEP12732686.6T patent/LT2729579T/lt unknown
- 2012-07-09 DK DK12732686.6T patent/DK2729579T3/en active
- 2012-07-09 JP JP2014517844A patent/JP6397762B2/ja not_active Expired - Fee Related
- 2012-07-09 PH PH1/2014/500063A patent/PH12014500063A1/en unknown
- 2012-07-09 CA CA2840149A patent/CA2840149C/en active Active
- 2012-07-09 CN CN201280033813.XA patent/CN103732759A/zh active Pending
- 2012-07-09 EA EA201400117A patent/EA034232B1/ru not_active IP Right Cessation
- 2012-07-09 ES ES12732686.6T patent/ES2654561T3/es active Active
- 2012-07-09 WO PCT/EP2012/063436 patent/WO2013007702A1/en not_active Ceased
- 2012-07-09 HU HUE12732686A patent/HUE036036T2/hu unknown
- 2012-07-09 US US14/131,445 patent/US10626462B2/en active Active - Reinstated
- 2012-07-09 HR HRP20180001TT patent/HRP20180001T1/hr unknown
- 2012-07-09 AU AU2012282528A patent/AU2012282528B2/en not_active Ceased
- 2012-07-09 BR BR112014000443-9A patent/BR112014000443B1/pt not_active IP Right Cessation
-
2014
- 2014-01-02 IL IL230303A patent/IL230303B/en active IP Right Grant
- 2014-01-06 ZA ZA2014/00089A patent/ZA201400089B/en unknown
-
2020
- 2020-03-10 US US16/814,321 patent/US11261499B2/en not_active Expired - Fee Related
-
2022
- 2022-01-18 US US17/577,836 patent/US12110558B2/en active Active
-
2024
- 2024-08-30 US US18/821,050 patent/US20250101527A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005040421A2 (en) * | 2003-10-17 | 2005-05-06 | Martin Widschwendter | Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues |
| WO2007118704A2 (en) * | 2006-04-17 | 2007-10-25 | Epigenomics Ag | Methods and nucleic acids for the detection of colorectal cell proliferative disorders |
| CN101688239A (zh) * | 2007-02-12 | 2010-03-31 | 约翰·霍普金斯大学 | 结肠癌的早期检测和预后 |
Non-Patent Citations (1)
| Title |
|---|
| 陈昊宾等: "K-ras与大肠癌关系的研究进展", 《西南国防医药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114561452A (zh) * | 2022-03-10 | 2022-05-31 | 天津市人民医院 | mSEPT9作为预测结直肠癌患者术后复发风险标志物及用于评价化疗方案有效性的应用 |
| CN115029462A (zh) * | 2022-08-10 | 2022-09-09 | 中国农业科学院农业质量标准与检测技术研究所 | 一种动植物疫病的核酸标准物质、形貌模拟方法及其应用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12110558B2 (en) | Methods and nucleic acids for determining the prognosis of a cancer subject | |
| AU2008207110B2 (en) | Methods and nucleic acids for analyses of cell proliferative disorders | |
| EP2044215B1 (en) | Methods for analyses of cellular proliferative disorders of the prostate | |
| AU2007237444B2 (en) | Methods and nucleic acids for the detection of colorectal cell proliferative disorders | |
| US20190119760A1 (en) | Methods and nucleic acids for analyses of cellular proliferative disorders | |
| EP2261366B1 (en) | Methods and nucleic acids for the analysis of CpG methylation associated with the development of prostate cell proliferative disorders | |
| WO2009092597A2 (en) | Methods and nucleic acids for analyses of prostate cancer | |
| US20110171637A1 (en) | Methods and nucleic acids for analyses of cellular proliferative disorders | |
| HK1197754B (en) | Methods and nucleic acids for determining the prognosis of a cancer subject | |
| HK1197754A (en) | Methods and nucleic acids for determining the prognosis of a cancer subject | |
| HK1172373A (en) | Methods and nucleic acids for the detection of colorectal cell proliferative disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |